ARTICLE | Top Story
Genzyme, Peptimmune obesity deal
May 10, 2004 7:00 AM UTC
GENZ granted Peptimmune (Cambridge, Mass.) an exclusive worldwide license to develop and market GT389-255 to treat obesity. Peptimmune plans to file an IND this year for GT389-255, a dual action pancr...